藿香正气口服液治疗特应性皮炎:CHARM随机对照试验
CHARM多中心双盲随机对照试验纳入218例轻中度特应性皮炎或湿疹成人患者,随机给予藿香正气口服液或安慰剂治疗4周。第4周藿香正气组EASI评分较基线下降幅度优于安慰剂组,第8周EASI改善≥50%的患者比例更高,提示其可改善皮损清除。
要点
- 藿香正气口服液治疗4周可较安慰剂更多降低轻中度AD/湿疹患者EASI评分。
- 第8周藿香正气组EASI改善≥50%者达66%,高于安慰剂组的50.5%。
- 研究仅纳入轻度AD/湿疹且疗程4周,长期获益尚不明确。
核心结论
- 在轻度特应性皮炎/湿疹成人患者中,藿香正气口服液第4周EASI评分下降优于安慰剂,并在8周内显示更好的皮损清除获益。
研究设计与样本
- 多中心、双盲、随机对照试验(CHARM研究),共纳入218例轻度AD或湿疹成人患者,随机接受藿香正气口服液(n=110)或安慰剂(n=108)治疗4周。
主要发现
- 意向性分析中,第4周EASI评分较基线变化的两组校正差值(组间差异)为-0.44(95%CI:0.83,-0.04;p=0.033)。
- 第8周时,藿香正气组70例(66%)患者EASI评分较基线改善≥50%,安慰剂组为53例(50.5%)(p=0.022)。
关键数值与推荐
- 主要结局为基线至治疗结束时EASI评分变化,两组校正差值为-0.44(95%CI:0.83,-0.04;p=0.033)。
- 第8周EASI改善≥50%的比例:藿香正气组66%(70例)vs 安慰剂组50.5%(53例),p=0.022。
临床怎么用
- 对轻度AD/湿疹成人患者,可考虑在规范治疗基础上短期试用藿香正气口服液以改善皮损,但需注意证据仅限4周疗程与轻度人群。
局限性
- 仅观察轻度AD或湿疹患者;治疗时长仅4周,无法充分确定藿香正气口服液的长期临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an unmet treatment need and a lack of efficacy evidence for Huoxiang Zhengqi (HXZQ) oral liquid for atopic dermatitis (AD). OBJECTIVES: To assess the therapeutic efficacy and safety profile of HXZQ therapy in adult Chinese patients with AD or eczema. METHODS: In the CHARM study (a multi-center, double-blind, randomized controlled trial), randomized participants with mild AD or eczema received HXZQ or a placebo for 4 weeks randomly. The primary outcome was the change in the Eczema Area and Severity Index (EASI) scores from baseline to the end of treatment. Several secondary outcomes were also measured. RESULTS: In total, 218 participants were enrolled who received either HXZQ (n = 110) or a placebo (n = 108). The adjusted difference in the change in the EASI score from baseline to Week 4 between the two groups was -0.44 (95 % confidence interval [CI]:0.83, -0.04; p = 0.033) in the intention-to-treat analysis. At Week 8, 70 participants (66 %) in the HXZQ group had a 50 % or greater reduction from baseline in the EASI score, as compared with 53 participants (50.5 %) in the placebo group (p = 0.022). LIMITATIONS: Only mild AD or eczema participants were observed; due to the limited 4-week treatment timeframe, HXZQ oral liquid's long-term clinical benefits could not be fully determined. CONCLUSIONS: In participants with mild AD/eczema, treatment with HXZQ oral liquid resulted in greater EASI reduction than treatment with placebo at Week 4, and had more benefits in skin clearance benefits over 8 weeks.
引用
- Xuan M, Guo X, Li G, et al. Chinese herbal formula Huoxiang Zhengqi Qral liquid for atopic dermatitis: The CHARM randomized controlled trial. Phytomedicine. 2025. PMID: 40839987. doi:10.1016/j.phymed.2025.157141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。